» Articles » PMID: 33466447

Novel Epigenetic Eight-Gene Signature Predictive of Poor Prognosis and MSI-Like Phenotype in Human Metastatic Colorectal Carcinomas

Abstract

Epigenetics is involved in tumor progression and drug resistance in human colorectal carcinoma (CRC). This study addressed the hypothesis that the DNA methylation profiling may predict the clinical behavior of metastatic CRCs (mCRCs). The global methylation profile of two human mCRC subgroups with significantly different outcome was analyzed and compared with gene expression and methylation data from The Cancer Genome Atlas COlon ADenocarcinoma (TCGA COAD) and the NCBI GENE expression Omnibus repository (GEO) GSE48684 mCRCs datasets to identify a prognostic signature of functionally methylated genes. A novel epigenetic signature of eight hypermethylated genes was characterized that was able to identify mCRCs with poor prognosis, which had a CpG-island methylator phenotype (CIMP)-high and microsatellite instability (MSI)-like phenotype. Interestingly, methylation events were enriched in genes located on the q-arm of chromosomes 13 and 20, two chromosomal regions with gain/loss alterations associated with adenoma-to-carcinoma progression. Finally, the expression of the eight-genes signature and MSI-enriching genes was confirmed in oxaliplatin- and irinotecan-resistant CRC cell lines. These data reveal that the hypermethylation of specific genes may provide prognostic information that is able to identify a subgroup of mCRCs with poor prognosis.

Citing Articles

Spatial deconvolution from bulk DNA methylation profiles determines intratumoral epigenetic heterogeneity.

Liu B, Xie Y, Zhang Y, Tang G, Lin J, Yuan Z Cell Biosci. 2025; 15(1):7.

PMID: 39844296 PMC: 11756021. DOI: 10.1186/s13578-024-01337-y.


The mechanisms and drug therapies of colorectal cancer and epigenetics: bibliometrics and visualized analysis.

Tian S, Chen M Front Pharmacol. 2024; 15:1466156.

PMID: 39268463 PMC: 11391208. DOI: 10.3389/fphar.2024.1466156.


Pan-cancer analysis and single-cell analysis reveals FAM110B as a potential target for survival and immunotherapy.

Li Y, Li X, Wu B, Su S, Su Y, Guo L Front Mol Biosci. 2024; 11:1424104.

PMID: 39170745 PMC: 11335499. DOI: 10.3389/fmolb.2024.1424104.


Large-scale external validation and meta-analysis of gene methylation biomarkers in tumor tissue for colorectal cancer prognosis.

Yuan T, Wankhede D, Edelmann D, Kather J, Tagscherer K, Roth W EBioMedicine. 2024; 105:105223.

PMID: 38917511 PMC: 11255517. DOI: 10.1016/j.ebiom.2024.105223.


The cuproptosis-related gene UBE2D2 functions as an immunotherapeutic and prognostic biomarker in pan-cancer.

Fei Y, Cao D, Dong R, Li Y, Wang Z, Gao P Clin Transl Oncol. 2024; 26(10):2718-2737.

PMID: 38703335 DOI: 10.1007/s12094-024-03495-4.


References
1.
Testa U, Pelosi E, Castelli G . Colorectal cancer: genetic abnormalities, tumor progression, tumor heterogeneity, clonal evolution and tumor-initiating cells. Med Sci (Basel). 2018; 6(2). PMC: 6024750. DOI: 10.3390/medsci6020031. View

2.
Watanabe T, Kobunai T, Toda E, Yamamoto Y, Kanazawa T, Kazama Y . Distal colorectal cancers with microsatellite instability (MSI) display distinct gene expression profiles that are different from proximal MSI cancers. Cancer Res. 2006; 66(20):9804-8. DOI: 10.1158/0008-5472.CAN-06-1163. View

3.
Yu G, Wang L, Han Y, He Q . clusterProfiler: an R package for comparing biological themes among gene clusters. OMICS. 2012; 16(5):284-7. PMC: 3339379. DOI: 10.1089/omi.2011.0118. View

4.
Yang X, Lay F, Han H, Jones P . Targeting DNA methylation for epigenetic therapy. Trends Pharmacol Sci. 2010; 31(11):536-46. PMC: 2967479. DOI: 10.1016/j.tips.2010.08.001. View

5.
Nikolsky Y, Sviridov E, Yao J, Dosymbekov D, Ustyansky V, Kaznacheev V . Genome-wide functional synergy between amplified and mutated genes in human breast cancer. Cancer Res. 2008; 68(22):9532-40. DOI: 10.1158/0008-5472.CAN-08-3082. View